GermanyGermany

As global demand for meat rises, Evonik steps up lysine production

01.10.2011

Essen – German specialty chemicals supplier Evonik Industries plans to double its output capacity for recombinantly expressed L-lysine, a growth accelerator in animal feed. Product­ion will be scaled up to 280,000 tonnes per year. Evonik is currently planning a two-stage expansion of the plant that it operates jointly with US company Cargill in Nebraska. With the completion of the first stage, additional production capacity will already commence in November of this year. “This investment will further strengthen our market position in the important area of feed additives,” said Evonik Industries CEO Klaus Engel.
The highly competitive market for essential amino acids is largely dominated by low-cost Asian suppliers. Among other products, Evonik offers all four essential amino acids, which are used for feeding pigs and poultry. Three of them are hetero­logously expressed by microorganisms, including L-lysine. The market is growing due to a rise in global meat consumption, which is forcing manufacturers to produce cost­-effectively. Feed additives offer major potential for savings, as they help reduce expensive fish or soy flour costs. When given them, the animals also excrete less nitro­gen and consume less water. “We have seen an increased demand for our lysine,” says Engel. The site in Nebraska is a prime example for an efficient biorefinery, as it is run by several companies. Cargill refines sugar from corn, which serves as a basis for Evonik lysine production. Right next door, NatureWorks LLC uses the same raw material to make biopolymers for packaging and textile fibers.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-germany/article/as-global-demand-for-meat-rises-evonik-steps-up-lysine-production.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.97 EUR11.43%
  • PROSENSA (NL)10.24 USD5.89%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK5.71%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • STENTYS (F)7.26 EUR-12.32%

TOP

  • WILEX (D)2.70 EUR221.4%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK49.8%
  • Allergy Therapeutics (UK)20.00 GBP33.3%

FLOP

  • HYBRIGENICS (F)1.68 EUR-28.5%
  • METABOLIC EXPLORER (F)2.88 EUR-21.3%
  • VITA 34 (D)4.16 EUR-20.6%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)418.50 GBP634.2%
  • PAION (D)2.50 EUR290.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.0%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.16 EUR-71.0%

No liability assumed, Date: 01.08.2014


Current issue

All issues

Product of the week

Products